thymosin beta-4 fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-01 and is reviewed periodically as new material appears.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
== Further reading == Laurence J. Alison, Marie Eyre: Killer in the Shadows: The Monstrous Crimes of Robert Napper. Pennant Books 2009, ISBN 978-1-906015-49-7. Kevin Brewer: Psychology and Crime. Heinemann Educational Publishers 2000, ISBN 978-0-435-80653-8. Paul Britton: The Jigsaw Man. Corgi Books 1998, ISBN 978-0-552-14493-3. Colin Evans: A Question of Evidence: The Casebook of Great Forensic Controversies, from Napoleon to O.J. Wiley 2002, ISBN 978-0-471-44014-7. Mike Fielder: The Murder of Rachel Nickell. John Blake 2000, ISBN 978-1-85782-338-7. Alex Handscombe: Letting Go: A true story of murder, loss and survival by Rachel Nickell's son. Harper Element 2017, ISBN 978-0008144296. André Hanscombe: The Last Thursday in July. Century 1996 / Arrow 1997, ISBN 978-0-09-917512-4. David Kessler: Rachel Nickell, House of Solomon Ltd, 2001, ISBN 978-1-904037-03-3. Keith Pedder: The Rachel Files, John Blake 2002, ISBN 978-1-904034-30-8. Keith Pedder: Murder on the Common: The Secret Story of the Murder That Shocked a Nation. John Blake 2003, ISBN 978-1-84454-057-0. Colin Stagg, David Kessler: Who Really Killed Rachel? Greenzone Publishing 1999, ISBN 978-0-9582027-2-5. Colin Stagg, David Kessler: The Lizzie James Conspiracy. House of Solomon 2001, ISBN 978-1-904037-00-2. Colin Stagg, Ted Hynds: Pariah: Colin Stagg. Pennant Publishing 2007, ISBN 978-1-906015-10-7. Brent E. Turvey: Criminal Profiling: An Introduction to Behavioral Evidence Analysis Academic Press 2002, ISBN 978-0-12-705041-6.
AMH measurements may be less accurate if the person being measured is vitamin D deficient. Note that males are born with higher AMH levels than females in order to initiate sexual differentiation, and in women, AMH levels decrease over time as fertility decreases as well.
=== Withdrawal === The incidence of antidepressant discontinuation syndrome symptoms in men using dapoxetine to treat PE has been described by reviewers as low or no different from the incidence of such symptoms in men withdrawn from placebo treatment. The lack of chronic serotonergic stimulation with on-demand dapoxetine minimizes the potentiation action of serotonin at synaptic cleft, thus decreasing the risk of discontinuation symptoms.
== Species distribution and evolution == In addition to mammals, NF-κB is found in a number of simple animals as well. These include cnidarians (such as sea anemones, coral and hydra), porifera (sponges), single-celled eukaryotes including Capsaspora owczarzaki and choanoflagellates, and insects (such as moths, mosquitoes and fruitflies). The sequencing of the genomes of the mosquitoes A. aegypti and A. gambiae, and the fruitfly D. melanogaster has allowed comparative genetic and evolutionary studies on NF-κB. In those insect species, activation of NF-κB is triggered by the Toll pathway (which evolved independently in insects and mammals) and by the Imd (immune deficiency) pathway.
Sources: en.wikipedia.org
=== Distributor development === American building materials supplier Johns Manville noted in the years before the US entered World War II that distributors needed support in a range of practical areas if they were going to be successful in connecting with housing developers, and instituted "Housing Guilds" which brought together the distributor (as the materials supplier), design services, sub-contractors, local realtors and housing financiers. Laurence C. Hart refers to the extensive development of these guilds and the "Training Schools" which they operated, converting these into a radio-based program from 1942. Hart, who worked for the supplier, put this experience forward to the American Marketing Association as "an outstanding example of manufacturer-distributor collaboration on an industry-wide basis". Companies wishing to grow through sales to new markets may need to identify and develop relationships with local distributors, for example to support export to new markets. In southeast Asia, for example, many distributors have a head office in Singapore which can be used by manufacturers outside the region to increase their regional market penetration and grow sales.
The three substrates of this enzyme are (R)-mevalonate, coenzyme A (CoA), and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are (S)-3-hydroxy-3-methylglutaryl-CoA, reduced NADPH, and two protons. This enzyme belongs to the family of oxidoreductases, to be specific those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in biosynthesis of steroids including cholesterol. The statin class of anticholesterol drugs act through inhibiting this enzyme.
While most of the general design and progress through the game levels remains the same as Half-Life, the largest change in Black Mesa is the reworking of the game's final chapter, Xen, which was generally considered the weakest part of the original game. Black Mesa also includes support for the individual and Team Deathmatch multiplayer modes from Half-Life on similarly updated maps.
Sources: en.wikipedia.org
== Medicine == Researchers in 2011 discovered the ability of graphene to accelerate the osteogenic differentiation of human mesenchymal stem cells without the use of biochemical inducers. In 2015 researchers used graphene to create biosensors with epitaxial graphene on silicon carbide. The sensors bind to 8-hydroxydeoxyguanosine (8-OHdG) and is capable of selective binding with antibodies. The presence of 8-OHdG in blood, urine and saliva is commonly associated with DNA damage. Elevated levels of 8-OHdG have been linked to increased risk of several cancers. By the next year, a commercial version of a graphene biosensor was being used by biology researchers as a protein binding sensor platform. In 2016 researchers revealed that uncoated graphene can be used as neuro-interface electrode without altering or damaging properties such as signal strength or formation of scar tissue. Graphene electrodes in the body are significantly more stable than electrodes of tungsten or silicon because of properties such as flexibility, bio-compatibility and conductivity.
== Generation of the TCR diversity == The generation of TCR diversity is similar to that for antibodies and B-cell antigen receptors. It arises mainly from genetic recombination of the DNA-encoded segments in individual somatic T cells by somatic V(D)J recombination using RAG1 and RAG2 recombinases. Unlike immunoglobulins, however, TCR genes do not undergo somatic hypermutation, and T cells do not express activation-induced cytidine deaminase (AID). The recombination process that creates diversity in BCR (antibodies) and TCR is unique to lymphocytes (T and B cells) during the early stages of their development in primary lymphoid organs (thymus for T cells, bone marrow for B cells). Each recombined TCR possess unique antigen specificity, determined by the structure of the antigen-binding site formed by the α and β chains in case of αβ T cells or γ and δ chains on case of γδ T cells.
The International Union of Pure and Applied Chemistry (IUPAC ) is an international federation of National Adhering Organizations working for the advancement of the chemical sciences, especially by developing nomenclature and terminology. It is a member of the International Science Council (ISC). IUPAC is registered in Zürich, Switzerland, and its administrative office, known as the "IUPAC Secretariat", is in Research Triangle Park, North Carolina, United States. IUPAC was established in 1919 as the successor of the International Congress of Applied Chemistry for the advancement of chemistry. Its members, the National Adhering Organizations, can be national chemistry societies, national academies of sciences, or just other bodies representing chemists. There are a total of fifty-four National Adhering Organizations and three Associate National Adhering Organizations. IUPAC's Inter-divisional Committee on Nomenclature and Symbols (IUPAC nomenclature) is the recognized world authority in developing standards for naming chemical elements and compounds. Since its creation, IUPAC has been run by many different committees with different responsibilities. These committees run different projects; of those which include standardizing nomenclature, finding ways to bring chemistry to the world, and publishing works. IUPAC is best known for its works standardizing nomenclature in chemistry, but they have publications in many science fields including chemistry, biology, and physics.
== Genetics == HCP is caused by mutations in CPOX, which codes for the enzyme coproporphyrinogen oxidase. This enzyme is responsible for the sixth step in the heme biosynthetic pathway, converting coproporphyrinogen III to protoporphyrinogen IX. CPOX is located at 3q11.2-q12.1, has 6 introns and 7 exons and produces an mRNA strand that is 2675 bases in length. It is inherited in an autosomal dominant fashion, meaning that a deficiency of 50% of the normal enzyme activity is enough to cause symptoms. As reproductive fitness is not impacted, homozygous affected individuals have been reported. Along with other acute porphyrias HCP demonstrates reduced penetrance, meaning not all individuals who carry a disease-causing mutation will express symptoms. Individuals who are homozygous for a specific mutation (K404E) or compound heterozygous with a null allele in CPOX have a more severe erythropoietic porphyria, harderoporphyria, characterized by neonatal jaundice, hyperbilirubinemia, hepatosplenomegaly and skin lesions upon exposure to ultraviolet light. HCP is a rare disease, but the exact incidence is difficult to determine due to the reduced penetrance of the acute porphyrias. Overall, the incidence of all porphyrias is estimated at 1:20,000 in the United States. The incidence of harderoporphyria is even lower, with less than 10 cases reported worldwide.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.